Compare IROQ & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IROQ | ENTX |
|---|---|---|
| Founded | 1883 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.6M | 74.7M |
| IPO Year | 2011 | 2018 |
| Metric | IROQ | ENTX |
|---|---|---|
| Price | $27.72 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 16.3K | ★ 214.4K |
| Earning Date | 01-30-2026 | 03-27-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 72.44 | N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $28,552,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.94 | ★ N/A |
| Revenue Growth | 17.86 | ★ 25.25 |
| 52 Week Low | $23.00 | $1.00 |
| 52 Week High | $29.00 | $3.22 |
| Indicator | IROQ | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 49.47 |
| Support Level | $27.41 | $1.45 |
| Resistance Level | $28.99 | $1.49 |
| Average True Range (ATR) | 0.40 | 0.17 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 32.98 | 75.76 |
IF Bancorp Inc is a holding company mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company, in association, takes deposits from the general public and invests those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, etc., and offers a variety of deposit accounts and alternative delivery channels. In addition to the traditional banking products and services, the group also offers a full line of property and casualty insurance products, annuities, mutual funds, individual securities, managed accounts, and other financial services.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.